CAS NO: | 1445179-97-4 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor ofJNK. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | D-JNKI-1 (AM-111; 1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells[1]. | ||||||||||||||||
体内研究 (In Vivo) | D-JNKI-1 (AM-111; 10 μM) prevents nearly all hair cell death and permanent hearing loss induced by neomycin ototoxicity in the scala tympani of the guinea pig cochlea. Local delivery of D-JNKI-1 also prevents acoustic trauma-induced permanent hearing loss in a dose-dependent manner[1]. D-JNKI-1 (0.3 mg/kg, i.p.) reverses these pathological events in the brain mitochondria of the rat and almost completely abolishes cytochrome c release and PARP cleavage[2]. D-JNKI-1 (1 μg/kg, s.c.) results in a significant decrease in the disease activity index, and reduces the expression of CD4+and CD8+cells in mice[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 3822.44 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C164H286N66O40 | ||||||||||||||||
CAS 号 | 1445179-97-4 | ||||||||||||||||
Sequence Shortening | DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-NH2 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(26.16 mM) H2O : ≥ 50 mg/mL(13.08 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|